Nuvectis Pharma (NVCT) Accumulated Expenses (2021 - 2026)

Nuvectis Pharma has disclosed Accumulated Expenses across 6 years of filings, most recently posting $6.4 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $6.4 million, up 645.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.4 million (up 645.32% YoY), and the FY2025 annual result was $6.9 million, up 24.32% from the prior year.
• Accumulated Expenses came in at $6.4 million for Q1 2026 at Nuvectis Pharma, down from $6.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $6.9 million in Q4 2025 to a low of $75000.0 in Q3 2025.
• The 5-year median for Accumulated Expenses is $486000.0 (2024), against an average of $1.8 million.
• Across the five-year window, Accumulated Expenses surged 1576.76% in 2022 and tumbled 82.57% in 2023, its largest moves.
• Nuvectis Pharma's Accumulated Expenses stood at $2.4 million in 2022, then sank by 82.57% to $415000.0 in 2023, then soared by 1238.8% to $5.6 million in 2024, then gained by 24.32% to $6.9 million in 2025, then decreased by 6.66% to $6.4 million in 2026.
• The last three Accumulated Expenses figures came in at $6.4 million (Q1 2026), $6.9 million (Q4 2025), and $75000.0 (Q3 2025), per Business Quant data.